牛牛AI助理已提取核心訊息
On February 9, 2024, Shattuck Labs, Inc., a Delaware-incorporated biotechnology company, announced the entry into a significant collaboration and license agreement with Ono Pharmaceutical Co., Ltd. The agreement, effective February 13, 2024, will see both companies working together on the research and preclinical development of certain compounds from Shattuck's pipeline of bifunctional fusion proteins, targeting areas selected by Ono. Shattuck will lead the research activities under a joint research committee's oversight. Shattuck has granted Ono an exclusive option to license the resulting products globally, with the option period lasting until 90 days post the delivery of Shattuck's final research report. Financially, Shattuck stands to receive up to $9 million for initial and milestone payments during the research phase, and potentially up to...Show More
On February 9, 2024, Shattuck Labs, Inc., a Delaware-incorporated biotechnology company, announced the entry into a significant collaboration and license agreement with Ono Pharmaceutical Co., Ltd. The agreement, effective February 13, 2024, will see both companies working together on the research and preclinical development of certain compounds from Shattuck's pipeline of bifunctional fusion proteins, targeting areas selected by Ono. Shattuck will lead the research activities under a joint research committee's oversight. Shattuck has granted Ono an exclusive option to license the resulting products globally, with the option period lasting until 90 days post the delivery of Shattuck's final research report. Financially, Shattuck stands to receive up to $9 million for initial and milestone payments during the research phase, and potentially up to $217.5 million in additional milestone payments, plus royalties on global net sales, should Ono exercise its licensing option. The agreement also includes provisions for termination under certain conditions, including material breach and insolvency. Shattuck plans to file the full Collaboration Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.
2024年2月9日，特拉華州註冊的生物技術公司Shattuck Labs, Inc. 宣佈與小野製藥有限公司簽訂了一項重要的合作和許可協議。該協議自2024年2月13日起生效，兩家公司將共同研究和臨床前開發Shattuck雙功能融合蛋白產品線中的某些化合物，目標是小野選擇的領域。沙特克將在聯合研究委員會的監督下領導研究活動。Shattuck已授予小野在全球範圍內對由此產生的產品進行獨家許可的期權，期權期限持續到Shattuck的最終研究報告發布後的90天。財務方面，如果小野行使許可權，Shattuck將在研究階段獲得高達900萬美元的初始和里程碑付款，並可能獲得高達2.175億美元的額外里程碑付款，外加全球淨銷售額的特許權使用費。該協議還包括在某些條件下終止的條款，包括重大違約和破產。Shattuck計劃將完整的合作協議作爲其截至2024年3月31日的季度10-Q表季度報告的附錄提交。
2024年2月9日，特拉華州註冊的生物技術公司Shattuck Labs, Inc. 宣佈與小野製藥有限公司簽訂了一項重要的合作和許可協議。該協議自2024年2月13日起生效，兩家公司將共同研究和臨床前開發Shattuck雙功能融合蛋白產品線中的某些化合物，目標是小野選擇的領域。沙特克將在聯合研究委員會的監督下領導研究活動。Shattuck已授予小野在全球範圍內對由此產生的產品進行獨家許可的期權，期權期限持續到Shattuck的最終研究報告發布後的90天。財務方面，如果小野行使許可權，Shattuck將在研究階段獲得高達900萬美元的初始和里程碑付款，並可能獲得高達2.175億美元的額外里程碑付款，外加全球淨銷售額的特許權使用費。該協議還包括在某些條件下終止的條款，包括重大違約和破產。Shattuck計劃將完整的合作協議作爲其截至2024年3月31日的季度10-Q表季度報告的附錄提交。
有用
沒用